A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)

NCT00632931 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer Relapsed
Advanced Cancer Refractory

Interventions

DRUG: vorinostat
DRUG: Comparator: placebo (unspecified)

Sponsor

Merck Sharp & Dohme LLC